Onconetix, Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on men's health and oncology diagnostics. Registration statements, amendments, proxy materials, and current reports describe securities offerings, preferred stock and warrant terms, common-stock structure, shareholder voting matters, and reverse-stock-split authorizations.
The company's SEC reports also disclose governance changes, board and executive appointments, material agreements, operating and financial results, clinical or regulatory matters, and risk factors related to its commercial-stage biotechnology business and Proclarix prostate cancer diagnostic.
HRT Financial LP, a ten percent owner of Onconetix, Inc., reported an open-market sale of 49,710 Class A Shares at $0.69 per share. After this transaction, HRT Financial LP directly holds 33,649 Class A Shares of Onconetix.
This Form 4 reflects a net reduction in HRT Financial LP’s position, with no derivative securities reported as remaining holdings in this filing.
HRT Financial LP, a ten percent owner of Onconetix, Inc., reported several open-market trades in Class A Shares. On April 16, 2026 and April 20, 2026 it sold a total of 148,329 shares at about $0.73–$0.75 per share, and on April 17, 2026 it purchased 34,636 shares at $0.73. Overall, this was a net sale of 113,693 shares, leaving HRT Financial LP with 83,359 Class A Shares held directly after the last reported transaction.
Onconetix, Inc. major holder HRT FINANCIAL LP increased its stake with open-market purchases of Class A Shares. The investor bought 92,554 shares at $0.76 per share on April 15, 2026 and 74,350 shares at $0.77 per share on April 14, 2026. After these transactions, HRT FINANCIAL LP directly holds 197,052 Class A Shares, reflecting net buying activity over the two days.
Onconetix, Inc. disclosed that HRT FINANCIAL LP is a ten percent owner and filed an initial ownership report. The filing shows HRT FINANCIAL LP directly holds 104,498 Class A Shares of Onconetix common equity. This is a status report of existing holdings, not a new purchase or sale.
Onconetix provides an update on its pending acquisition of Realbotix LLC, stating it entered into a definitive share exchange to acquire 100% of the issued and outstanding equity interests of Realbotix LLC in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions.
Onconetix highlights Realbotix’s April 8, 2026 delivery of the first Vinci-equipped humanoid robot to Ericsson. Vinci is described as a patented AI vision and eye-tracking system that enables Realbotix robots to recognize returning users, recall prior conversations, maintain eye contact, and track engagement; Vinci can be added to any Realbotix robot model.
Onconetix, Inc. summarizes Realbotix's update that Realbotix expects delivery of 19 previously ordered humanoid robots and associated AI implementations across March, April, and May 2026. Onconetix previously entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all‑stock transaction. The combined company is expected to trade on Nasdaq following closing, which Onconetix anticipates in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions. Onconetix states it will file a Registration Statement on Form S-4 to register shares to be issued in the transaction.
Onconetix, Inc. appointed David White as Chief Executive Officer effective March 18, 2026 and Sammy Dorf as a director and Audit Committee member effective March 19, 2026.
The company states these leadership changes come as it advances a definitive agreement to acquire Realbotix LLC and intends to file a Registration Statement on Form S-4 to register Onconetix common stock to be issued in the transaction.
Onconetix, Inc. is asking stockholders at an April 30, 2026 special meeting to approve authority for one or more reverse stock splits of its common stock at ratios between 1-for-2 and 1-for-10, with all such splits together capped at 1-for-100 and usable for one year.
The aim is to maintain compliance with Nasdaq’s $1.00 minimum bid requirement after prior notices under the Bid Price Rule and Low Priced Stocks Rule, and to support liquidity and future capital-raising. A second proposal would allow adjournment of the meeting to solicit additional proxies. There were 692,927 common shares outstanding as of March 13, 2026.
Onconetix, Inc. filed an initial insider ownership report for Chief Executive Officer David Allan White on Form 3. This filing establishes his status as an executive officer and subject to insider reporting rules, but it does not disclose any specific stock transactions or option exercises.
Onconetix, Inc. director Sammy Dorf filed an initial ownership report on Form 3. This filing establishes his status as a director and brings his equity position under Section 16 reporting, but it does not list any transactions, purchases, or sales of Onconetix stock.